A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-31

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor.

Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected.

The main questions it aims to answer are:

1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection
2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

NCT00747474

Advanced Solid Tumors

COMPLETED PHASE1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937

Small Cell Lung Cancer Melanoma Prostate Cancer +1 more

NOT_YET_RECRUITING PHASE1

Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors

NCT06770569

Advanced Solid Tumors

RECRUITING PHASE1

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

NCT01755390

Advanced Solid Tumor

COMPLETED PHASE1

Study of Intravenous RXDX-107 in Patients With Solid Tumors

NCT02548390

Solid Tumor

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Malignancies, Cancer Solid Cancers Solid Tumor Cancer Solid Tumor, Unspecified, Adult Solid Tumour Solid Tumors Refractory to Standard Therapy HCC - Hepatocellular Carcinoma RCC, Renal Cell Cancer Pancreas Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LXP1788 Injection will be administered intravenously once a week in a 28-day treatment cycle.

Group Type EXPERIMENTAL

LXP1788 is administered intravenously via Port-A

Intervention Type DRUG

LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LXP1788 is administered intravenously via Port-A

LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written (signed) Informed Consent.
2. Male or female ≥ 18 years old.
3. Life expectancy \> 8 weeks.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
5. A histologically or cytologically confirmed, advanced solid tumor that is refractory to currently available therapies or for which no effective treatment is available.
6. Measurable disease per RECIST 1.1.
7. Willing to have a tumor biopsy or having tissue sample from a previous biopsy available in the tissue bank for analysis that had been collected in the past 3 years.

Exclusion Criteria

1. Significant concurrent medical diseases, such as congestive heart failure, unstable angina, acute or recent myocardial infarction (\< 6 months before enrollment), COPD with frequent exacerbations, uncontrolled hypertension (systemic blood pressure \>= 160 mmHg and/or diastolic blood pressure \>= 100 mmHg with or without anti-hypertensive medication), recent CVA (\< 6 months before enrollment), or active infection which requires treatment withintravenous antibiotics.
2. Patients with symptomatic CNS metastases who are neurologically unstable, receiving radiotherapy for the CNS lesion, or requiring increasing dose of steroids to control their CNS disease.

Asymptomatic patients with metastatic brain disease who have been on a stable dose of steroids for less than 14 days prior to screening.
3. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

Bone marrow:
* Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L
* Platelet count \< 100 x 10\^9/L
* Hemoglobin \< 9 g/dL
* Having had a blood transfusion within 2 weeks of screening date is also not allowed.

Hepatic:
* Total bilirubin \> 1.5 x ULN
* AST and ALT \> 3 x ULN if no liver metastases
* AST and ALT \> 5 x ULN in the presence of liver metastases

Renal:

⚫ Estimated creatinine clearance (CrCL) \< 60 mL/min per the Cockcroft and Gault formula
4. Known history of human immunodeficiency virus (HIV)-1 or -2 infection.
5. Psychiatric disorders that would compromise the patient's compliance or ability to give consent.
6. Major surgical intervention within 4 weeks of the first dose of LXP1788 Injection or with ongoing postoperative complications.
7. Toxicities from any prior therapy, surgery, or radiotherapy that did not resolve to grade 0 or 1 as per the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, with the exception of alopecia, skin hyperpigmentation or hypopigmentation.
8. Underlying medical conditions that, in the investigator's opinion, will make the administration of LXP1788 Injection hazardous or obscure the interpretation of toxicities or adverse events.
9. Exposure to any other investigational or commercial anti-cancer agents or curative therapies within 28 days or 5 half-lives (whichever is shorter), before the first dose of LXP1788 Injection. Exposure to radiation therapy for non-curative purposes or pain control may be permitted under the judgement of the investigator.
10. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions, or requirements.
11. Pregnancy or breast feeding.
12. Women or men of childbearing potential not willing to use effective means of contraception.
13. Positive test for hepatitis B (HBsAg) or hepatitis C (positive HCV antibody with detectable HCV RNA).
14. History of allergic reactions to any component of LXP1788 Injection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No